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Jan WernermanAbstract
The lack of understanding of the mechanisms behind
possible beneficial and possible harmful effects of
glutamine supplementation makes the design of
interventional studies of glutamine supplementations
difficult, perhaps even hazardous. What is the
interventional target, and how might it relate to
outcomes? Taking one step further and aggregating
results from interventional studies into meta-analyses
does not diminish the difficulties. Therefore,
conducting basic research seems to be a better idea
than groping in the dark and exposing patients to
potential harm in this darkness.confusing.Introduction
Meta-analyses do not bring much clarity over the pos-
sible beneficial effect of glutamine supplementation to
critically ill patients. This is related to five issues: (a) The
patients with hypoglutaminemia, who are the ones who
have an association between a possible glutamine short-
age and unfavorable outcomes, have never been properly
investigated. (b) The mechanism that associated hypo-
glutaminemia with enhanced morbidity and mortality is
not known. (c) The artificial separation according to
route of administration has not been very helpful in
interpreting the results. (d) The variable doses of glu-
tamine and the combination with other nutrients have
further blurred the interpretation of results. Finally, (e)
the absence of characterization of nutritional status of
the patients studied and the variable time course of crit-
ical illness at supplementation also contribute to the dif-
ficulty to digest the results presented.Correspondence: jan.wernerman@karolinska.se
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A situation in which mechanism of action is not under-
stood makes the meta-analysis technique particularly
hazardous. The impact of route of administration, dos-
ing, combination with other nutrients, definition of
shortage, and time course of treatment all call for sub-
group analyses in which the individual studies in the end
will stand quite alone with their specific treatment pro-
tocols. Meta-analyses may be a useful tool when the
mechanism of action is known and the peculiarities of
the individual studies can be evaluated in that context.
When the mechanism is obscure, results become much
more speculative, and the value of combining studies
into a meta-analysis is discounted and may even become
Until today, only one study provides plasma glutamine
concentration at the time of study start [1]. It is unfortu-
nate that the study protocol did not select the patients
with hypoglutaminemia to randomization. Another un-
fortunate factor is that the intervention was not confined
to glutamine supplementation but also included omega-
3 fatty acids, and therefore post hoc subgroup analyses
of the hypoglutaminemic subject did not shed any light
on the effect of glutamine supplementation in that par-
ticular group. So to summarize, the hypothesis that glu-
tamine supplementation may be beneficial in critically ill
patients with hypoglutaminemia is still not addressed.Mechanism of action
The failure to understand the mechanism that associates
hypoglutaminemia with an unfavorable outcome in crit-
ical illness is a crucial issue. Much more effort should be
spent on exploring the pathophysiology of hypoglutami-
nemia in critically ill subjects. Extrapolation of results
from animal studies has not been very helpful. Patients
with hyperglutaminemia obviously do not need supple-
mentation. This is a small group within the critically ill
patients, often associated with hepatic failure [2, 3]. This
is not confined to patients with acute fulminant liver
failure but also applies to a large fraction of the patientsis distributed under the terms of the Creative Commons Attribution 4.0
.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
ive appropriate credit to the original author(s) and the source, provide a link to
changes were made. The Creative Commons Public Domain Dedication waiver
ro/1.0/) applies to the data made available in this article, unless otherwise stated.
Wernerman Critical Care  (2015) 19:385 Page 2 of 3with chronic or acute-on-chronic liver failure. Hyperglu-
taminemia may also occur in other critically ill patients
and is shown to be associated with an unfavorable out-
come [3]. Also, a high, but normal, plasma glutamine
concentration during glutamine supplementation is re-
lated to post-intensive care unit (post-ICU) mortality
[4]. In this case, however, this was strongly related to
discharge Sequential Organ Failure Assessment (SOFA)
scoring, making interpretation difficult. Overall, the
mechanism behind hypo- and hyperglutaminemia and
the relation to outcome in critical illness need to be fur-
ther explored before starting up new treatment studies
or new meta-analyses of earlier studies with the limita-
tions in patient characteristics outlined above.
Route of administration
In studies of nutrition support in the critically ill, it is a
conventional approach to separate studies according to
the route of nutrient administration. The background is
the belief that the enteral route is superior to the paren-
teral. A number of studies comparing the two routes of
administration have been published over the years, and
an even larger number of meta-analyses have tried to
summarize the results. The main problem with the stud-
ies has been whether or not the compared patient
groups have really been comparable in gastrointestinal
function and in nutrition intake. A recent study, per-
formed in a modern ICU setting, failed to demonstrate
any clinically relevant difference in outcomes related to
route of administration. So the question remains of
whether a differentiation of route of administration is
relevant for glutamine supplementation. Plasma concen-
tration is affected differently related to the route of ad-
ministration [5], but is that a sufficient rationale to
include or exclude studies in a summary? Again, the ab-
sence of mechanistic knowledge is striking. The difference
in effect sometimes claimed may well be attributable to
the fact that patients possible to feed by the enteral route
are different from the patients not possible to feed by the
enteral route, even if their risk scoring is identical.
Conventional parenteral nutrition excludes glutamine
because of the instability of crystalline glutamine in aque-
ous solution. It is only by providing glutamine as a dipep-
tide that the amino acid component of parenteral nutrition
becomes complete. Therefore, supplementing parenteral
nutrition to have a glutamine content equivalent to that of
enteral nutrition is not a controversial issue and therefore
should be excluded from the discussion of specific glutam-
ine supplementation. Nobody has suggested that glutamine
be excluded from nutrition products.Dosing of supplementation
The dosing in glutamine supplementation has been to-
tally arbitrary, regardless of whether the target has beento obtain a “pharmacological” effect or to substitute a
shortage. In either case, successful treatment in terms of
“immune parameters” or plasma glutamine concentra-
tion has not been related to the dose given. In the only
dose-finding study published in the critically ill, it was
demonstrated that the plasma glutamine level of
healthy subjects is always possible to reach, but with an
individualized dose [6]. The rationale of high or low
doses in virtually all publications stays with the authors
and has not been objectively verified. Therefore, separ-
ating high and low doses in a meta-analysis without
better subject characterization does not seem to be a
meaningful exercise.
Nutritional status
Although the effect of nutrition is most likely related to
nutritional status of the subjects receiving treatment, it
is rare to find a nutritional characterization of included
critically ill subjects in nutritional studies, beyond body
mass index (BMI). There are observational reports that
low and high BMI are risk factors for an unfavorable out-
come in the critically ill [7]. This may be a reflection of
the fact that total muscle mass is a predictor for outcomes,
as suggested from radiologic estimations of muscle mass
[8]. Nutritional characterization of included subjects is, of
course, necessary in nutritional studies, and if subjects at a
nutritional risk are systematically excluded, the external
validity of result is correspondingly limited.
Conclusions
To summarize, to substitute knowledge of the under-
lying mechanisms affected by an intervention, and
thereby knowledge of the patients most likely to benefit
from the intervention, by integrating studies with insuffi-
cient characterization of treatment and subjects into a
meta-analysis will not expand knowledge. It may be
hypothesis-generating if, by luck, relevant elements of the
mechanism were included in the patient characterization.
At a time when the underlying mechanism is not known,
conducting basic research seems to be a much better idea
than groping in the dark and exposing patients to poten-
tial harm in this darkness.
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